Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Stopped early

Conditions studied: Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

In brief

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

Key facts

Study ID

NCT03436771

Run by

Juno Therapeutics, a Subsidiary of Celgene

People needed

4

Starts

2018-02-19

Expected to finish

2018-07-20

Last updated by the study team

2020-05-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have received at least one dose of a Juno CAR T-cell product (listed above) in a Juno-sponsored clinical trial
• Patients who have provided informed consent for the long-term follow-up study

You may not qualify if…

• None. All patients who have previously received treatment with a Juno CAR T-cell product are eligible for this long-term follow-up study.

Where it is running

• City of Hope — Duarte, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.